Coming Soon: Phase III Trial For Inhaled Alpha-1 Antitrypsin Therapy
Source: Pixabay

Coming Soon: Phase III Trial For Inhaled Alpha-1 Antitrypsin Therapy

The pharmaceutical company, Kamada, has just submitted its proposed Phase III protocol for an inhaled alpha-1 antitrypsin therapy (inhaled AAT) to the U.S. Food and Drug Administration (FDA). This therapy…

Continue Reading Coming Soon: Phase III Trial For Inhaled Alpha-1 Antitrypsin Therapy
Close Menu